Cystatin C (CysC) is an independent risk factor for adverse outcomes in patients with HF across the ejection fraction (EF) spectrum.

What exactly happens in the hearts of patients with heart failure with preserved ejection fraction (HFpEF)—and how can this ...

Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...

EAT index measured by CMR may identify high-risk HFpEF patients and predict outcomes. Learn more about its role in risk ...

Heart failure with preserved ejection fraction (HFpEF) has limited treatment options and remains a medical challenge. HFpEF is characterized by diastolic dysfunction with a normal ejection fraction.

Most trials that have shown a benefit of beta-blocker treatment after myocardial infarction included patients with large myocardial infarctions and were conducted in an era before modern ...

Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a ...

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure that affects the left side of the heart. It occurs when the lower left chamber of the heart, called the left ventricle ...

Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.